Latest news with #Trulicity
Time of India
a day ago
- Health
- Time of India
Need a testosterone boost? New study suggests trying weight-loss drugs like Ozempic
We're circling back to the age-old idea of hitting two birds with one stone! The medication that's widely prescribed to manage diabetes and used for weight loss as well – is now showing promise to offer some more exceptional health perks. Recent research suggests that GLP‑1 receptor agonists, like Ozempic, Wegovy, Mounjaro, and Trulicity, might offer an unexpected hormonal benefit. A recently presented ENDO 2025 study tracked 110 men over 18 months, revealing a remarkable rise in testosterone from 53% to 77% of normal levels, alongside about 10% average weight loss. These findings hint that by targeting fat reduction, insulin resistance, inflammation, and estrogen-to-testosterone conversion, these drugs could offer a dual boost for metabolic and men's health. Read on to know more. The GLP‑1–Testosterone breakthrough GLP‑1 receptor agonists – such as semaglutide (Ozempic/Wegovy), dulaglutide (Trulicity), and tirzepatide (Mounjaro/Zepbound) – work by mimicking the gut hormone GLP‑1 to suppress appetite, slow digestion, and improve insulin secretion. Now, testosterone is a hormone that fuels male sex drive and erectile function and influences everything from bone density and muscle mass to fat distribution, red blood cell production, mood, and energy levels. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like นี่อาจเป็นโอกาสทองที่ดีที่สุดในรอบ 5 ปีสำหรับการเทรดทองคำ IC Markets อ่านเพิ่มเติม Undo Unfortunately, testosterone levels naturally decline with age. Older men may feel more tired and grouchy, and less interested in sex. Not to mention the hair loss, bone fractures, and weight gain around the waist that often accompany low T. Luckily, there are ways to naturally boost testosterone. Exercise, especially strength training, a healthy diet, stress reduction, adequate sleep, and weight management, particularly for those who are overweight, are just a few. This new study highlights another tool that may help elevate these levels — Ozempic and other GLP-1 drugs. Endocrinology fellow Dr. Shellsea Portillo Canales and the research team analyzed the records of 110 adult men with obesity or Type 2 diabetes taking the weight-loss medications semaglutide (Wegovy), dulaglutide (Trulicity), or tirzepatide (Zepbound) but not participating in testosterone or hormonal therapy. These three drugs mimic the effects of GLP-1, a natural hormone in the body that regulates blood sugar and appetite, often leading to lower blood sugar and weight loss. At the ENDO 2025 conference , the team shared data showing men on these drugs experienced ~10% weight loss and significant testosterone increases (from 53% to 77% of normal) over 18 months. Mechanisms include reduced aromatase in shrinking fat, improved insulin sensitivity, and lower systemic inflammation – key drivers supporting testosterone production. The convincing evidence A 2025 meta-analysis (n=680) of seven GLP‑1 RA trials found a pooled increase in total testosterone of 1.39 ng/mL, with parallel gains in free testosterone, LH, FSH, weight loss, and HbA1c reduction. Liraglutide (Saxenda) was observed to restore gonadotropin signaling and improve testosterone in obese men, without the hormonal axis suppression typical of testosterone replacement therapy. However, a 2021 cohort in men with type 2 diabetes (n=51) showed only modest testosterone increases, primarily in men whose baseline testosterone was under 320 ng/dL or had ≥1% HbA1c reduction, reinforcing the importance of weight loss and insulin control. How does weight impact testosterone levels in males? In men, weight, particularly excess body fat, is inversely related to testosterone levels. Increased body fat, especially around the abdomen, is associated with lower testosterone, while weight loss, particularly through lifestyle changes, can lead to increased testosterone levels. As per research , weight loss can enhance testosterone levels because excess body fat contains the enzyme aromatase, which converts testosterone into estrogen. As reported by the NY Post, Dr. Shellsea Portillo Canales, an endocrinology fellow at SSM Health St. Louis University Hospital in Missouri, said, 'While it is well-known that weight loss from lifestyle changes or bariatric surgery increases testosterone levels, the impact that anti-obesity medications may also have on these levels has not been widely studied,' adding, 'Our study is among the first to provide compelling evidence that low testosterone can be reversed with the use of commonly prescribed anti-obesity medications. ' Portillo Canales also said, 'Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,' adding, 'Doctors and their patients can now consider this class of medications not only for the treatment of obesity and to control blood sugar, but also to benefit men's reproductive health.' The way ahead Although initial findings from ENDO 2025 and earlier trials are encouraging, longer randomized controlled trials (RCTs) are essential to confirm direct effects on fertility, muscle mass, mood, and safety of GLP‑1 therapies. If you're considering a testosterone boost without traditional hormone therapy, GLP‑1 agents like Ozempic may offer a compelling path: addressing weight, metabolic health – and testosterone – together. Talk to your endocrinologist to explore whether this novel approach fits your needs and goals. Always approach treatment under medical guidance – monitoring weight, hormones, metabolic health, fertility, and side effects. Study suggests digital apps can help chronic pain sufferers
New York Post
2 days ago
- Health
- New York Post
Weight loss drugs like Ozempic can raise low testosterone — what that means for men
Big gland energy! Testosterone fuels male sex drive and erectile function and influences everything from bone density and muscle mass to fat distribution, red blood cell production, mood and energy levels. Unfortunately, testosterone levels naturally decline with age. Older men may feel more tired and grouchy and less interested in sex. Not to mention the hair loss, bone fractures and weight gain around the waist that often accompany low T. Advertisement 3 Testosterone levels significantly affect a man's physical, sexual and mental well-being. AntonioDiaz – Luckily, there are ways to naturally boost testosterone. Exercise, especially strength training, a healthy diet, stress reduction, adequate sleep and weight management, particularly for those who are overweight, are just a few. A new study highlights another tool that may help elevate these levels — Ozempic and other GLP-1 drugs. Advertisement Research indicates that weight loss can enhance testosterone levels because excess body fat contains the enzyme aromatase, which converts testosterone into estrogen. 'While it is well-known that weight loss from lifestyle changes or bariatric surgery increases testosterone levels, the impact that anti-obesity medications may also have on these levels has not been widely studied,' said Dr. Shellsea Portillo Canales, an endocrinology fellow at SSM Health St. Louis University Hospital in Missouri. 'Our study is among the first to provide compelling evidence that low testosterone can be reversed with the use of commonly prescribed anti-obesity medications.' 3 Ozempic and other GLP-1 drugs may help elevate testosterone levels through weight loss. mbruxelle – Advertisement Portillo Canales' team analyzed the records of 110 adult men with obesity or Type 2 diabetes taking the weight-loss medications semaglutide (Wegovy), dulaglutide (Trulicity) or tirzepatide (Zepbound) but not participating in testosterone or hormonal therapy. These three drugs mimic the effects of GLP-1, a natural hormone in the body that regulates blood sugar and appetite, often leading to lower blood sugar and weight loss. On average, the participants experienced 10% weight loss and saw their testosterone levels rise from 53% to 77% over 18 months. Advertisement Weight loss improves insulin sensitivity, reduces inflammation and lowers aromatase activity, which contribute to increased testosterone production. The findings were presented Monday at ENDO 2025, the Endocrine Society's meeting in San Francisco. 'Results from this study show that there is a direct correlation between the use of anti-obesity medications and testosterone levels,' said Portillo Canales. 'Doctors and their patients can now consider this class of medications not only for the treatment of obesity and to control blood sugar, but also to benefit men's reproductive health.' 3 It's important to keep an eye on testosterone levels, which naturally decline with age. Larisa – GLP-1 drugs are not without risks, though. Nausea, vomiting and diarrhea are among the most commonly reported side effects. Inflammation of the pancreas, vision changes, stomach paralysis and even death are rare but serious concerns. Advertisement In the 20 years since the first GLP-1 drug was approved to treat diabetes, researchers have been exploring other uses for these popular meds. Research continues on their potential to slow the progression of Alzheimer's disease, improve sleep apnea, reduce alcohol cravings and treat liver disease, among other conditions.
Yahoo
16-06-2025
- Business
- Yahoo
The Zacks Analyst Blog Highlights Eli Lilly, Home Depot, SAP and Natural Resource Partners
Chicago, IL – June 16, 2025 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. LLY, The Home Depot, Inc. HD, SAP SE SAP and Natural Resource Partners L.P. NRP. Here are highlights from Friday's Analyst Blog: The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., The Home Depot, Inc., and SAP SE, as well as one micro-cap stock, Natural Resource Partners L.P.. The Zacks microcap research is unique, as our research content on these small and under-the-radar companies is the only research of its type in the country. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. You can see all of today's research reports here >>> Ahead of Wall Street The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page, and can actually sign up there to get an email notification as this article comes out each morning. You can read today's AWS here >>> Israel Attacks on Iran Send Markets into the Red Shares of Eli Lilly and Co. have fallen -6.5% over the past year against the Zacks Large Cap Pharmaceuticals industry's decline of -12.4%. Declining sales of Trulicity, rising pricing pressure on some drugs, and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds for Eli Lilly. However, demand for Eli Lilly's popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company's key top-line drivers. Though their sales were below expectations in the second half of 2024, they picked up in the first quarter, driven by launches of the drugs in new international markets and improved supply from ramped-up production. (You can read the full research report on Eli Lilly and Company here >>>) Home Depot's shares have outperformed the Zacks Retail - Home Furnishings industry over the past year (+4.4% vs. +0.3%). The company continues to benefit from its progress in building an interconnected shopping experience, synergies from the SRS acquisition, expansion of its Pro ecosystem, strategic digital investments, and new store openings. These factors contributed to robust top-line growth in the first quarter of fiscal 2025, driven by increased engagement in Spring-related purchases and smaller-scale home improvement projects. However, HD faces softer demand in big-ticket discretionary categories, reflecting consumer caution amid high interest rates. Margin pressure, currency headwinds, and macroeconomic uncertainty also remain key risks. (You can read the full research report on Home Depot here >>>) Shares of SAP have outperformed the Zacks Computer – Software industry over the past year (+57.2% vs. +13.3%). SAP is gaining momentum in the cloud business, especially the Cloud ERP Suite and the rising adoption of its Rise with SAP and Grow with SAP solutions. Steady growth in the Cloud backlog also bodes well. SAP remains confident in its growth trajectory and has reaffirmed its outlook, expecting cloud revenues of €21.6-€21.9 billion for 2025, up 26–28% at constant currency from €17.14 billion in 2024. However, ongoing softness in the software license and services business continues to weigh on performance. In the first quarter, software license revenues declined 10% year over year, while services revenue fell 1%. (You can read the full research report on SAP here >>>) Shares of Natural Resource Partners have declined -11.3% year to date against the Zacks Coal industry's decline of -11.8%. Natural Resource Partners faces significant headwinds from declining coal and soda ash prices. Metallurgical and thermal coal prices fell 50% year over year in 2024, pressuring royalties, while lower thermal coal demand adds risks. Soda ash distributions from Sisecam Wyoming dropped $43 million to $39 million due to a 60% price collapse, with management expecting prolonged weakness. NRP's 2024 free cash flow was $251 million, which is expected to decline sharply in 2025, limiting distributions and debt repayment. Dependence on a concentrated customer base, weak carbon sequestration prospects, regulatory pressures and declining U.S. coal exports threaten earnings. (You can read the full research report on Natural Resource Partners here >>>) Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Eli Lilly and Company (LLY) : Free Stock Analysis Report The Home Depot, Inc. (HD) : Free Stock Analysis Report SAP SE (SAP) : Free Stock Analysis Report Natural Resource Partners LP (NRP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Advertiser
03-06-2025
- Health
- The Advertiser
Surgery risk flagged for popular weight-loss, diabetes drugs in new warning
Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic and Wegovy. The Therapeutic Goods Administration (TGA) said there was a "known potential" for these medicines to delay the passage of food through the stomach which adds a "potential risk" for patients under general anaesthesia or deep sedation. The TGA warning advised patients to tell their health professionals, including anaesthetists, if they are taking one of these medicines before surgery or a procedure. The usual fasting period before these procedures may not empty the stomach sufficiently, the TGA warned. The warning covers glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs. Six medicines are currently marketed in Australia: GLP-1 RAs Ozempic, Trulicity and Victoza for the management of adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. GIP/GLP-1 RA Mounjaro for both type 2 diabetes and chronic weight management. Seven cases of aspiration and one case of pneumonia aspiration for semaglutide, one case of aspiration and one case of pneumonia aspiration for liraglutide and one case of pneumonia aspiration for dulaglutide were identified in a search of the publicly available Database of Adverse Event Notification (DAEN). All cases were reported with a single suspected medicine according to the TGA. They have required the product information for each medicine to be updated on the risks. The full details of the update is found on the TGA website here. Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic and Wegovy. The Therapeutic Goods Administration (TGA) said there was a "known potential" for these medicines to delay the passage of food through the stomach which adds a "potential risk" for patients under general anaesthesia or deep sedation. The TGA warning advised patients to tell their health professionals, including anaesthetists, if they are taking one of these medicines before surgery or a procedure. The usual fasting period before these procedures may not empty the stomach sufficiently, the TGA warned. The warning covers glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs. Six medicines are currently marketed in Australia: GLP-1 RAs Ozempic, Trulicity and Victoza for the management of adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. GIP/GLP-1 RA Mounjaro for both type 2 diabetes and chronic weight management. Seven cases of aspiration and one case of pneumonia aspiration for semaglutide, one case of aspiration and one case of pneumonia aspiration for liraglutide and one case of pneumonia aspiration for dulaglutide were identified in a search of the publicly available Database of Adverse Event Notification (DAEN). All cases were reported with a single suspected medicine according to the TGA. They have required the product information for each medicine to be updated on the risks. The full details of the update is found on the TGA website here. Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic and Wegovy. The Therapeutic Goods Administration (TGA) said there was a "known potential" for these medicines to delay the passage of food through the stomach which adds a "potential risk" for patients under general anaesthesia or deep sedation. The TGA warning advised patients to tell their health professionals, including anaesthetists, if they are taking one of these medicines before surgery or a procedure. The usual fasting period before these procedures may not empty the stomach sufficiently, the TGA warned. The warning covers glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs. Six medicines are currently marketed in Australia: GLP-1 RAs Ozempic, Trulicity and Victoza for the management of adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. GIP/GLP-1 RA Mounjaro for both type 2 diabetes and chronic weight management. Seven cases of aspiration and one case of pneumonia aspiration for semaglutide, one case of aspiration and one case of pneumonia aspiration for liraglutide and one case of pneumonia aspiration for dulaglutide were identified in a search of the publicly available Database of Adverse Event Notification (DAEN). All cases were reported with a single suspected medicine according to the TGA. They have required the product information for each medicine to be updated on the risks. The full details of the update is found on the TGA website here. Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic and Wegovy. The Therapeutic Goods Administration (TGA) said there was a "known potential" for these medicines to delay the passage of food through the stomach which adds a "potential risk" for patients under general anaesthesia or deep sedation. The TGA warning advised patients to tell their health professionals, including anaesthetists, if they are taking one of these medicines before surgery or a procedure. The usual fasting period before these procedures may not empty the stomach sufficiently, the TGA warned. The warning covers glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs. Six medicines are currently marketed in Australia: GLP-1 RAs Ozempic, Trulicity and Victoza for the management of adults with type 2 diabetes, and Saxenda and Wegovy for chronic weight management. GIP/GLP-1 RA Mounjaro for both type 2 diabetes and chronic weight management. Seven cases of aspiration and one case of pneumonia aspiration for semaglutide, one case of aspiration and one case of pneumonia aspiration for liraglutide and one case of pneumonia aspiration for dulaglutide were identified in a search of the publicly available Database of Adverse Event Notification (DAEN). All cases were reported with a single suspected medicine according to the TGA. They have required the product information for each medicine to be updated on the risks. The full details of the update is found on the TGA website here.
Health Line
02-06-2025
- Business
- Health Line
Does Medicare Cover Trulicity?
Medicare Part D plans and some Part C plans may cover Trulicity (dulaglutide) for diabetes, but the exact coverage depends on the plan. Such plans will only cover this drug for weight loss in certain cases if you're living with obesity. Trulicity (dulaglutide) is a drug belonging to the glucagon-like peptide-1 receptor agonist (GLP-1) class of medications. Diabetes affects 38.4 million people in the United States, or 11.6% of the population. The Food and Drug Administration (FDA) has approved this drug to help manage type 2 diabetes and reduce the chance of developing heart disease. For this reason, although GLP-1s may be prescribed off-label for weight loss, Medicare Part D plans may cover this drug for diabetes management but not for weight loss, except under specific circumstances. Is Trulicity covered by Medicare Part B? Medicare is generally divided into the following parts: Original Medicare (parts A and B) Medicare Part D Medicare Part C (Medicare Advantage) Medigap Part B Part B mainly covers medications that you cannot administer yourself, such as IV infusions, for example. While Trulicity is an injection drug, it is one that you can inject yourself. For this reason, Medicare Part D would be responsible for covering a drug like Trulicity. Part D Since private insurers manage Part D plans, the exact drugs that each plan covers vary. What drugs a specific plan covers depends on its formulary, which is a list of the covered drugs. Part D plans are generally required to cover at least two drugs from the most commonly prescribed categories. If the plan does not cover Trulicity (dulaglutide), it is likely to cover some brand-name or generic alternative. Medicare's plan finder tool allows you to enter medications you take to see which Part D plans in your area include these medications in their formulary. The tool also lets you compare prices at different pharmacies in your area. Part C Medicare Part C, also called Medicare Advantage, is another option for healthcare coverage under Medicare. These optional, private plans offer the same benefits as Original Medicare. Some Part C plans may also offer other benefits, such as prescription drug coverage. Coverage for specific medications under a Medicare Advantage plan depends on the options and plans that the company you choose offers. When selecting a Medicare Advantage plan, you can specify medications you take to compare coverage and pricing. Why doesn't Medicare cover Trulicity for weight loss? Medicare drug plans typically cover medications when they are considered medically necessary. Therefore, Part D plans or Part C plans with drug coverage won't cover GLP-1 agonists like Trulicity for weight loss. Typically, coverage focuses on FDA-approved uses such as helping manage type 2 diabetes or lowering cardiovascular risks for overweight adults or those living with obesity. Obesity is defined as having a body mass index (BMI) of 30 or greater. This means you could have a BMI between 25 and 30, but would not qualify for a drug like Trulicity through Medicare unless you need it for diabetes. Under the Biden administration, the Centers for Medicare & Medicaid Services (CMS) looked into expanding coverage of GLP-1 drugs for weight loss by 2026. However, the Trump administration has since decided against this expansion. How much does Trulicity cost on Medicare? Trulicity's list price is $987.19 per month, but insurance or Medicare coverage may lower this cost. When a Medicare drug plan covers a drug, how much you'll pay out of pocket depends on the tier your plan classifies the drug within its formulary. Generally, higher-tier drugs cost more. Copays for this medication will vary based on the plan you choose, but the manufacturer suggests a range of $0 to $100 per month after you've met your Medicare Part D deductible. Generic drugs are generally classified in a lower tier, but no generic Trulicity is currently available. How can I lower the cost of Trulicity? Trulicity's manufacturer offers a savings card through which you can get a one-month supply of Trulicity for as little as $25. However, you won't be able to use your Medicare plan if you want this discount. Alternatively, you can check whether you qualify for Extra Help, which can lower your prescription costs to $4 to $9. Other resources for lowering drug costs include: Other tips that may help lower your prescription drug costs include: Ask your doctor about less expensive generic options. Consider switching from a 30-day supply to a 90-day supply for your medications, as buying a larger supply upfront can provide cost savings. Consider a mail-order supplier to save on costs. What is a cheaper alternative to Trulicity? The following chart shows GLP-1 agonists currently available in the United States and their brand-name retail prices before insurance. Available generic versions usually cost less. Brand name (generic name) List price as of 2025 Wegovy (semaglutide) $1,349.02 Ozempic (semaglutide) $997.58 Rybelsus (semaglutide $997.58 Mounjaro (tirzepatide) $1,079.77 Zepbound (tirzepatide) $1,086.37 Saxenda (liraglutide) $1,349.02 Victoza (liraglutide) $543.51 or $815.27 (depending on dose) Trulicity (dulaglutide) $987.19 In addition, other diabetes medications can be covered by Medicare. CMS included several of these drugs in the list of 10 drugs it used to renegotiate prices as part of the Inflation Reduction Act of 2022. Takeaway Trulicity is a long-lasting brand-name medication that can be quite effective at lowering high blood sugar levels due to type 2 diabetes. It is not a substitute for insulin or diet and lifestyle strategies for managing diabetes. There is no generic version of this medication. It is typically a tier 3 medication in most drug plan formulary lists. Many Medicare Part D plans include Trulicity on formularies, but you'll likely still pay a share of the costs. The cost you'll pay will depend on your specific plan. A variety of private and public programs offer extra help in covering your medication costs. You can also talk with your doctor about an affordable way to manage diabetes. The information on this website may assist you in making personal decisions about insurance, but it is not intended to provide advice regarding the purchase or use of any insurance or insurance products. Healthline Media does not transact the business of insurance in any manner and is not licensed as an insurance company or producer in any U.S. jurisdiction. Healthline Media does not recommend or endorse any third parties that may transact the business of insurance.
